Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study

Fig. 2

A Number of events and hazard ratio (CI 95%), for death and clinical outcomes in matched populations without previous cardiovascular disease according to treatment status. B Number of events and hazard ratio (CI 95%), for death and clinical outcomes in matched populations with previous cardiovascular disease according to treatment status. GLP-1RA glucagon-like peptide-1 receptor agonists, SGLT-2i sodium glucose transporter-2 inhibitors, MACE-3 all cause death, non-fatal myocardial infarction, non-fatal stroke, MACE-4 all-cause death, non-fatal myocardial infarction, non-fatal stroke, unstable angina

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840